A randomized, investigator-sponsored trial comparing active surveillance (AS) to SM-88 maintenance therapy in patients with prostate cancer

Trial Profile

A randomized, investigator-sponsored trial comparing active surveillance (AS) to SM-88 maintenance therapy in patients with prostate cancer

Planning
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2018

At a glance

  • Drugs SM 88 (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Feb 2018 New trial record
    • 30 Jan 2018 According to a Tyme Technologies media release, Mack Roach III, M.D., Professor of Radiation Oncology, Medical Oncology and Urology at the University of California, San Francisco (UCSF), will lead this trial. This trial will be conducted at UCSF and potentially expand to other academic sites.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top